ABPI Chief Executive talks about the importance of vaccines, as ABPI launches its new campaign, #ValuingVaccines.
With 10 million people a year projected to die from antibiotic-resistant infections by 2050, it’s important that all partners, including the pharmaceutical industry, step up and work together to tackle this issue.
In its second annual clinical trials report launched this week, the ABPI is calling for the research community to work with Government, funders, and the public to tackle issues around diversity and inclusion in research. This is essential, says ABPI President Haseeb Ahmad.
The Taskforce for Lung Health has been awarded Charity Collaboration of the Year at the Charity Times awards. Su Jones, NHS Engagement Partner at the ABPI and Dr Alison Cook, Chair of the Taskforce for Lung Health, explain the importance of the Taskforce and look to the future of its work.
As Gavi marks its twentieth anniversary, a new report from the ABPI and IFPMA looks at the past successes of the Vaccines Alliance and what the future holds.
On International Clinical Trials Day, Dr Sheuli Porkess considers the impact that COVID-19 is having on clinical trials and the potential lessons for the future research.
Malcolm Skingle CBE PhD, Chair of the ABPI's ACES Strategic Leadership Group, looks at the data from our most recent survey of academic-industry links.
COVID-19 has emerged as a brand new disease with a severe impact on patients, the public and health systems around the world.
The balance the Chancellor needs to strike in delivering his first Budget on Wednesday has been made even tougher by the need to prioritise measures to tackle coronavirus.
Our President Haseeb Ahmad sets out how industry is working to find treatments and cures for some of the world’s most complex diseases. Nowhere is the need to find new medicines more acute than in rare diseases, many of which are genetic and affect the youngest patients.